TESAMORELIN
- ≥99% purity by HPLC
- Janoshik COA with every lot
- Lot-traceable from synthesis
- EU-synthesised
Specifications
Third Party Lab Tested
Every lot is independently HPLC-tested by Janoshik Analytical, Europe's reference laboratory for peptide purity assessment. The COA shipped with your order is theirs, not ours.
Storage & Handling
Lyophilized peptides should be stored below 16°C, protected from light and moisture, for up to 24 months. Once reconstituted, refrigerate and use within 30 days for protocol consistency.
Reconstitution
Reconstitute with bacteriostatic water using the volumes below. Add solvent slowly along the inside wall of the vial. Swirl gently, never shake, until fully dissolved.
Lab-handling protocol BAC Water · 0.9% benzyl alcohol The reconstitution solvent referenced above. Add to order →Full-length
GHRH analog.
Tesamorelin is a 44-amino-acid GHRH analog with a stabilizing N-terminal modification that resists DPP-IV cleavage. Where Ipamorelin works on the ghrelin pathway, Tesamorelin amplifies the endogenous GHRH pulse directly - a different mechanism, with characteristic effects on visceral lipolysis in published research.
It is the most-studied GHRH analog in metabolic and body-composition research, and the closest pharmacological mimic of endogenous growth hormone-releasing hormone.
| Compound | Tesamorelin |
|---|---|
| Sequence length | 44 amino acids |
| Molecular mass | 5135.8 Da |
| Modeled half-life | ~30 min IV, longer SC |
| Mechanism / research class | Modified N-terminus. |
| Lab handling solvent | 2mL bacteriostatic water for injection (BWI) |
| Resulting concentration | Yields 0.5mg per 0.1mL |
| Supply format | 10MG · GHRH analog lyophilized research vial |
| Storage, lyophilized | store below 16°C for up to 24 months |
| Storage, reconstituted | refrigerate and use within 30 days |
Synthesised.
Verified.
Documented.
Backed by research.
Measured in results.
Each tag opens the cited literature behind that effect. References are linked to PubMed.
Tesamorelin is the most-studied GHRH analog in metabolic research. The reference clinical literature reports 15–18% reduction in visceral adipose tissue (VAT) at 26 weeks in HIV-associated lipodystrophy populations.
- Falutz J et al. Tesamorelin and visceral fat. NEJM. 2007;357(23):2359-2370. PubMed ↗
Unlike truncated GHRH analogs, Tesamorelin retains the full GHRH(1-44) sequence with a single stabilizing N-terminal modification, preserving native receptor binding and producing a sustained IGF-1 response in research models.
- Stanley TL et al. Tesamorelin in HIV-associated lipodystrophy. JCEM. 2014;99(5):1815-1820. PubMed ↗
Questions?
We got answers.
Show references
Used in published research.
4.6 / 5
Solid product, fast EU shipping
Ordered TESAMORELIN for a research-protocol pilot. Arrived in 4 days temperature-controlled, vials sealed and properly lyophilized. Reconstituted cleanly in BWI with no haze. Will reorder.
